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ABSTRACT
Objectives: Determine how general practitioners
(GPs) manage patients with cancer symptoms.
Design: GPs reviewed 24 video-vignettes and case
notes on patients with cancer symptoms and indicated
whether they would refer the patient and/or prescribe
medication, and/or undertake further investigation.
According to available guidelines, all cases warranted a
referral to a specialist or further investigations.
Setting: Australian primary care sector.
Participants: 102 practising GPs participated in this
study, including trainees.
Interventions: The research was part of a larger
randomised controlled trial testing a referral pro forma;
however, this paper reports on management decisions
made throughout the study.
Primary and secondary outcome measures: This
paper reports on how the participants would manage
the patients depicted in each vignette.
Results: In more than one-in-eight cases, the patient
was not investigated or referred. Patient management
varied significantly by cancer type (p<0.001). For two
key reasons, colorectal cancer was the chosen referent
category. First, it represents a prevalent type of cancer.
Second, in this study, colorectal cancer symptoms were
managed in a similar proportion of options—that is,
prescription, referral or investigation. Compared with
vignettes featuring colorectal cancer participants were
less likely to manage breast, bladder, endometrial, and
lung cancers with a ‘prescription only’ or ‘referral only’
option. They were less likely to manage prostate cancer
with a ‘prescription only’, yet more likely to manage it
with a ‘referral with investigation’. With regard to
pancreatic and cervical cancers, participants were more
likely to manage these with a ‘referral only’ or a ‘referral
with investigation’.
Conclusions: Some patients may receive a delayed
cancer diagnosis, even when they present with typical
cancer symptoms to a GP who can access relevant
diagnostic tests.
Trial registration number: ACTRN12611000760976.
INTRODUCTION
Australians who experience symptoms do not
have direct access to specialists, but are
required to consult a general practitioner
(GP) or attend an emergency department.1
Akin to other health systems,2 the Australian
health system positions GPs as the gatekeeper
to specialist services.3
In Australia, GPs can refer for a range of
tests including ultrasounds and CT scans
and, with speciﬁc indications, some MRI. In
some Australian jurisdictions, GPs can also
directly refer for gastroscopy and colonos-
copy. This represents a greater range of
tests relative to other health systems, like in
the UK.4
GP access to diagnostic tests is particularly
helpful in cancer care.5 It can optimise the
timely receipt of appropriate treatment and
as such reduce, if not avert, the personal,
social and economic costs of cancer.6–8 Given
the complexity of health systems, it can be
difﬁcult (if not impossible) to isolate deﬁni-
tive causal relationships between GP diagnos-
tic tests and cancer outcomes.9 10 However,
GP access to diagnostic tests is likely to help
identify those patients who require urgent
care.11
Strengths and limitations of this study
▪ Many Western nations position general practi-
tioners (GPs) as the gatekeeper to specialist ser-
vices, while enabling their access to diagnostic
tests. This can be particularly helpful in cancer
care.
▪ GPs were invited to review video-vignettes of
patients with possible cancer symptoms and
decide how they would manage these patients.
▪ There was limited evidence that appropriate tests
would be ordered, and a significant proportion
of high-risk cases were not immediately referred
for further investigation or specialist opinion.
▪ The study design did not examine the reasons
for the GP decisions.
▪ Some patients may receive a delayed cancer
diagnosis, even when they present with typical
cancer symptoms to a GP who can access rele-
vant diagnostic tests.
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As part of a larger pre–post, randomised control trial
of an interactive online referral pro forma,12 the review
of data reported here focused on how Australian GPs
manage patients with cancer symptoms. The interven-
tion tested in the original trial did not aim to guide GP
referral, investigation or prescribing practices—as such,
its focus is not germane to the focus of this review,
which encompasses data from both phases.12
METHODS
Following clearance from the relevant ethics committee,
the research team recruited GPs in seven Australian
states and territories to participate in this study via
email, newsletters and personal contact. Recruitment
was facilitated by primary care networks, university
departments, research networks and personal contacts.
GPs were eligible to participate if they were currently in
practice, including registrars (or vocational trainees),
and had internet access. As such, the exact number of
GPs who were aware of the project cannot be
ascertained.
Participants were invited to consider the symptoms of
patients presented as video-vignettes and to determine
how they would manage the patient. This was conducted
in two phases—before the participants were provided
with an interactive referral pro forma, and afterwards.
The pro forma aimed to improve the quantity and
quality of patient information communicated between
primary and secondary care clinicians. The focus of this
paper, however, is to determine how GPs respond to
patients with different cancer symptoms, regardless of
whether this was before or after using the pro forma.
Guided by the 2005 referral guidelines for suspected
cancer of the National Institute for Health and Clinical
Excellence (NICE),13 24 video-vignettes were developed
by six GPs, four videos for each of six cancer types
(table 1). These guidelines were selected as they indicate
the need for specialist referral based on speciﬁc high-
risk presentations; furthermore, at the time of the study,
no equivalent Australia-wide guidelines were available
for all cancer types. The video-vignettes comprised a
4 min video monologue delivered by an actor–patient
accompanied by case notes containing the patient’s
medical history, current medication, allergies and previ-
ous consultations. The video included an off-camera
commentary by an actor–doctor describing clinical signs
to be found at this visit.
After accessing a secured research website, partici-
pants: provided demographic information; received the
Table 1 Cancer cases
Cancer type Case details
Bladder 76-year-old woman with asymptomatic frank haematuria
Breast 35-year-old with asymptomatic, firm breast lump and skin dimpling
Breast 69-year-old with skin changes consistent with Paget’s disease of the breast
Cervical 34-year-old with CIN 2
Colorectal 60-year-old with unexplained iron deficiency anaemia, abdominal pain and right iliac fossa abdominal mass
Endometrial 65-year-old with PMB
Lung 58-year-old lifelong smoker with haemoptysis, breathlessness and weight loss
Oesophageal 66-year-old with 10 kg weight loss and dysphagia for solids
Pancreatic 57-year-old with 5 kg weight loss, jaundice, generalised pruritus and pancreatic mass on abdominal
ultrasound scan
Prostate 55-year-old with a PSA of 22, urinary frequency, haematuria, hesitancy and terminal dribbling
Lung 49-year-old smoker with cervical lymphadenopathy, haemoptysis and a 2 cm mass on chest X-ray
Colorectal 65-year-old with rectal bleeding, diarrhoea, fatigue and rectal mass
Bladder 65-year-old man with frank asymptomatic haematuria
Breast 38-year-old with a 3-month history of breast lump, dimpling of skin and axillary lymphadenopathy
Breast 71-year-old with a breast lump and peau d’orange
Cervical 36-year-old with CIN 2 and postcoital bleeding
Colorectal 62-year-old man with a 2-month history of constipation, abdominal pain, hepatomegaly and iron deficiency
anaemia
Endometrial 62-year-old with several episodes of PMB
Lung 60-year-old woman with cough, dyspnoea, weight loss, hoarseness, pleural effusion and clubbing
Lung 61-year-old man with cough, suspicious lesion on chest X-ray and haemoptysis
Oesophageal 69-year-old man with dysphagia for solids, weight loss, dyspepsia and fatigue
Pancreatic 60-year-old man with abdominal pain, chronic pancreatitis, weight loss, jaundice and pancreatic mass on
abdominal ultrasound scan
Prostate 70-year-old abnormal digital rectal examination findings, PSA of 25, chronic retention, prostatism and low back
pain
Colorectal 63-year-old woman with altered bowel habits, iron deficiency anaemia, abdominal pain, weight loss and rectal
bleeding
CIN, cervical intraepithelial neoplasia; PMB, postmenopausal bleeding; PSA, prostate-specific antigen.
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case notes of each patient; viewed the video-vignette of
the consultation once and received examination ﬁnd-
ings. Participants then chose to: (1) prescribe medica-
tion; (2) order diagnostic tests and/or (3) refer the
patient to a specialist. Participants documented the pre-
scription, the test, and/or the referral as they would
when consulting a bona ﬁde patient. Each participant
viewed and managed 24 video-vignettes.
Participants were recompensed for their participation
and could claim continuing medical education points.
Progress through the video-vignettes could be tracked
online and reminders were issued to those who had not
completed the study after 2 weeks of inactivity.
Statistical analysis
Descriptive statistics (number and percentage) were
used to report participants’ management of each scen-
ario, preintervention and postintervention. A multinom-
inal logistic model was used to assess the inﬂuence of
demographic information and specialty on the ways the
participants chose to manage the patient, with particular
reference to: ‘prescription only’, ‘investigation(s) only’,
‘referral only’ and ‘referral with investigation(s)’.
‘Investigation only’ was selected as the base outcome,
and the relative risk ratio of ‘prescription only’, ‘referral
only’ and ‘referral and investigation’ are reported.
User-deﬁned parsimonious models were constructed in
a backward elimination fashion from the full model.
The full model included: (1) participants’ demographic
data—notably age, gender, country of graduation,
number of years since graduation, years of GP
experience, Fellowship of the Royal Australian college
of General Practitioners (FRACGP), clinic remoteness
(4 categories: major cities, inner regional, outer regional
and remote/very remote), role within their primary
practice, patients consulted per week (3 categories:
<100, 100–149, ≥150), direct patient care hours per
week (4 categories: <11, 11–20, 21–40, ≥41),
non-English consultation (no and yes), number of GPs
within their primary practice, and number of patient ses-
sions per week and (2) cancer type. Only variables with
p<0.05 were retained in the ﬁnal model. The categories
of some variables were regrouped as noted, before they
were entered into the model, due to their small number.
In the regression, preintervention and postintervention
data were pooled according to cancer types. Given the
lack of independence between participant responses,
regression models were adjusted by estimating the
cluster effect using the ‘vce’ option within Stata. p
Values of <0.05 were considered statistically signiﬁcant.
Stata MP 13.1 (StataCorp, Texas, USA) was used to
perform the analysis.
RESULTS
Between August 2011 and August 2012 (inclusive), 102
GPs were recruited. Participants were mainly from
Western Australia (46%) and Victoria (25%), with a
mean age of 43 years (table 2). On average, the partici-
pants had 13 years of GP experience; however, 24% were
trainees. Most participants primarily practised in a
capital city or another metropolitan area.
Patient management varied by cancer case. Before the
intervention, relatively few participants managed the
patient with a ‘prescription only’ (range=1.0–10.8%,
mean=2.8%, table 3). After the intervention, more
chose to manage the patient with a ‘prescription’ (9.8–
32.6%, mean=21.5%) or an ‘investigation only’
(range=25.0–71.7%, mean=43.5%). Of all the demo-
graphic data pertaining to the doctors, the only factor
that appeared to inﬂuence their decisions was the geo-
graphical location of their practice (p<0.001 of the
overall Wald test after regression).
Patient management also varied signiﬁcantly by
cancer type (p<0.001 of the overall Wald test, table 4).
Colorectal cancer symptoms were managed almost
equally across the choice of options with a similar pro-
portion managed with each of the three options.
Compared to the management of colorectal cancer
symptoms, participants were less likely to manage breast,
bladder, endometrial and lung cancer symptoms with a
‘prescription’ or ‘referral only’. They were less likely to
manage prostate cancer with a ‘prescription only’, yet
more likely to manage it with a ‘referral with investiga-
tion’. With regard to pancreatic and cervical cancers,
participants were more likely to manage these with a
‘referral only’ or a ‘referral with investigation’, relative
to the management of colorectal cancer. Compared
with those who practised in a major city, participants
who practised in a remote or very remote practice were
signiﬁcantly less likely to opt for a ‘prescription’ or a
‘referral only’, yet more likely to manage the patient
with an ‘investigation only’ (see table 4). The investiga-
tions and treatment options suggested are presented in
table 5.
DISCUSSION
Findings
According to the 2005 NICE guidelines, all cases in this
study warranted a specialist review within 2 weeks.13 The
research results suggest that in more than one-in-eight
cases, the patient was not investigated or referred,
despite symptoms that were highly suggestive of cancer.
In some cases, the indication for the drugs prescribed
as per table 5 was unclear and in the case of
endometrial cancer, the prescription of oestrogen
replacement therapy may have actually advanced cancer
progression.18
Compared to cases presenting with colorectal symp-
toms, participants were more likely to refer a patient pre-
senting with symptoms of pancreatic, prostate or cervical
cancer, with or without further investigation. These
cases included relatively more objective signs of path-
ology sourced from a laboratory and/or radiological
report. This suggests that, despite the UK guidelines,
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Table 2 Participant demographics (n=102)
Participants National
comparisonMean SD
Age, years 43 11.8 50.5*
Years after graduation 19 11.3
Years as GP 13 11.1
GPs in primary practice 8 4.1
GP sessions/week 6 3.0
N° %
Male 58 56.9 60.9%†17
Graduated in Australia 73 71.6 65.9%†
GP registrar 24 23.5 3.8%‡
FRACGP 58 56.9 56.8¶
Accredited practice 101 99.0 88.6¶
Position
Principal 21 20.6
Non-principal 63 61.8
Other 18 17.6
State
New South Wales 13 12.7 33.1%‡
Queensland 7 6.8 19.5%‡
Victoria 25 24.5 25.1%‡
South Australia 7 6.9 8.4%‡
Tasmania 1 1.0 2.6%‡
Western Australia 47 46.1 9.1%‡
Australian Capital Territory 2 2.0 1.5%‡
Region of primary practice
Capital city 49 48.0 66.3%¶
Other metropolitan area 38 37.3 7.6%¶
Large rural area 5 4.9 6.7%¶
Small rural area 6 5.9 7.1%¶
Other rural area 3 2.9 10.6%¶
Remote centre 1 1.0 0.6%¶
Remoteness of the region
Major city 73 71.6 71.5%‡
Inner regional area 15 14.7 18.9%‡
Outer regional area 10 9.8 7.8%‡
Remote area 3 2.9 1.2%‡
Very remote area 1 1.0 0.6%‡
Patients consulted, per week
<100 49 48.0
100–149 30 29.4
150–199 20 19.6
>199 3 3.0
Direct patient care, h/week
<11 11 10.8 1.2%¶
11–20 21 20.6 12.2%¶
21–40 47 46.1 53%¶
41–60 20 19.6 32.1%¶
>60 3 2.9 1.4%¶
Non-English patient consultations, %
0 84 82.3 72.6%¶
<25 17 16.7 21.7%¶
25–50 0 0 2.9%¶
>50 1 1.0 2.8%¶
*Sourced from Britt et al14 and the Australian Institute of Health and Welfare.15
†Sourced from Britt et al.14
‡Sourced from General Practice Education and Training Limited.16
§Sourced from the Primary Health Care Research & Information Service.17
¶Compared to GPs involved in Britt et al.14
FRACGP, Fellowship of the Royal Australian college of General Practitioners; GP, general practitioners.
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Table 3 GP management decisions*
Cancer
Prescription
only
Investigation(s)
only Referral only
Referred with
investigation(s)
N° % N° % N° % N° %
Preintervention (n=102)
Bladder 1 1.0 58 56.9 16 15.7 27 26.5
Breast 3 2.9 71 69.6 15 14.7 13 12.7
Breast 11 10.8 53 52.0 16 15.7 22 21.6
Cervical 4 3.9 3 2.9 72 70.6 23 22.5
Colorectal 2 2.0 19 18.6 66 64.7 15 14.7
Endometrial 3 2.9 39 38.2 33 32.4 27 26.5
Lung 1 1.0 58 56.9 12 11.8 31 30.4
Oesophageal 1 1.0 23 22.5 49 48.0 29 28.4
Pancreatic 2 2.0 11 10.8 55 53.9 34 33.3
Prostate 1 1.0 13 12.7 65 63.7 23 22.5
Total 29 2.8 348 34.1 399 39.1 244 23.9
Postintervention (n=92)
Lung 25 27.2 38 41.3 18 19.6 11 12.0
Colorectal 35 38.0 20 21.7 30 32.6 7 7.6
Bladder 15 16.3 54 58.7 9 9.8 14 15.2
Breast 13 14.1 56 60.9 8 8.7 15 16.3
Breast 14 15.2 57 62.0 9 9.8 12 13.0
Cervical 20 21.7 33 35.9 19 20.7 20 21.7
Colorectal 21 22.8 34 37.0 21 22.8 16 17.4
Endometrial 15 16.3 46 50.0 12 13.0 19 20.7
Lung 9 9.8 66 71.7 5 5.4 12 13.0
Lung 18 19.6 42 45.7 15 16.3 17 18.5
Oesophageal 26 28.3 29 31.5 18 19.6 19 20.7
Pancreatic 30 32.6 23 25.0 29 31.5 10 10.9
Prostate 14 15.2 36 39.1 16 17.4 26 28.3
Colorectal 22 23.9 26 28.3 22 23.9 22 23.9
Total 277 21.5 560 43.5 231 17.9 220 17.1
*Percentages may not total 100% due to rounding.
Table 4 Factors associated with GP cancer management (n=2308)
Video
rrr (95% CI) rrr (95% CI) rrr (95% CI)
Prescription only vs
investigation(s) only
Referral only vs
investigation(s) only
Referral with
investigation(s) vs
investigation(s) only
Cancer (colorectal, rrr=1)
Breast 0.21 (0.14 to 0.32)*** 0.14 (0.09 to 0.22)*** 0.42 (0.28 to 0.65)***
Bladder 0.17 (0.10 to 0.30)*** 0.16 (0.09 to 0.27)*** 0.60 (0.37 to 0.95)*
Endometrial 0.26 (0.15 to 0.46)*** 0.37 (0.23 to 0.60)*** 0.88 (0.57 to 1.36)
Prostate 0.38 (0.20 to 0.73)** 1.18 (0.82 to 1.71) 1.65 (1.05 to 2.60)*
Pancreatic 1.17 (0.68 to 2.02) 1.78 (1.10 to 2.86)* 2.15 (1.30 to 3.56)**
Cervical 0.83 (0.51 to 1.36) 1.82 (1.30 to 2.54)*** 1.98 (1.30 to 3.02)***
Lung 0.32 (0.21 to 0.46)*** 0.17 (0.11 to 0.26)*** 0.57 (0.39 to 0.83)**
Oesophageal 0.64 (0.42 to 0.99)* 0.92 (0.63 to 1.34) 1.52 (1.01 to 2.29)*
Clinic remoteness (major city, rrr=1)
Inner regional 0.84 (0.44 to 1.62) 0.46 (0.29 to 0.73)*** 0.82 (0.38 to 1.75)
Outer regional 0.57 (0.17 to 1.95) 1.13 (0.50 to 2.51) 1.15 (0.50 to 2.64)
Remote/very remote 0.05 (0.01 to 0.25)*** 0.42 (0.26 to 0.67)*** 0.41 (0.09 to 1.83)
Results are rrr for the participant groups whose management was ‘prescription only’, ‘referral only’ or ‘referral with investigation’ compared to
those who selected ‘investigations only’ (rrr=1). Results were derived from one multinomial logistic regression with the adjustment of clustering
effect due to assessment of different cancers made by the same participant.
*p<0.05; **p<0.01; ***p<0.001.
rrr, relative risk ratio.
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these participants may have been reticent to refer
patients without further investigation—this was particu-
larly the case for breast, bladder, endometrial and lung
cancers where the patient presented with signs and
symptoms, without conﬁrmatory laboratory tests.
Notably, in the case of lung cancer, a suspicious lesion
on a chest X-ray did not appear to warrant immediate
referral in most cases.
The participants appeared to have different views on
how to manage patients with cancer symptoms—and the
reason for these opinions could not be gleaned (eg,
X-ray for endometrial cancer). This might suggest that
the participants collectively recognised both the advan-
tages and disadvantages associated with further investiga-
tion. The former may include the efﬁcient use of
limited diagnostic and subsequent specialist services.
This may be particularly advantageous for patients who
do not reside in close proximity to specialist services.
This was suggested by the study results, as participants
who practised in rural and remote locations were more
likely to request further investigation prior to referral;
yet research suggests that cancer outcomes in these loca-
tions are worse than in metropolitan areas.19 The disad-
vantages associated with locally conducted investigation
may include the ﬁnancial cost to the patient, as well as
delayed specialist advice and care.20
Strengths and weaknesses of the study
A key strength of this study is consistency in both the
cases reviewed by the participants and the way they
reviewed the cases. Furthermore, participants were
unaware of the case content before commencing the
study. As such, participants did not simply include GPs
with a particular interest in cancer care.
However, the study is limited in four key ways. First,
it did not enable interaction between the participant
and the patient, or the participant and the specialist.
Such communication is likely to promote effective
patient care. Second, data were not collected on review
plans to better understand the participants’ perspec-
tives on the case. This may be particularly relevant for
the option, ‘investigation only’, where a subsequent
review may help to conﬁrm a diagnosis and lead to
referral. Third, since the participants differed from
GPs who practise in Australia, the generalisability of
the ﬁndings is limited. Similarly, the number of partici-
pants from very remote areas was limited to four.
Finally, data were not collected on participants’ reasons
Table 5 Investigations requested and prescriptions per cancer type
Cancer type Investigations Prescriptions ordered
Breast Mammogram, fine-needle biopsy, full blood count, renal function
test, liver function test, ultrasound scan
Antifungals, antibiotic tablets or creams,
steroid creams, antihistamines
Lung CT scan/chest X-ray, ultrasound scan, fine-needle aspiration,
bronchoscopy, spirometry, lung biopsy, full blood count, renal
function test, liver function test, coagulation studies, ferritin, sputum
microscopy and culture/cytology, Mantoux test
Steroid tablets, antibiotics, diuretics,
codeine, steroid inhalers, β-agonist
inhalers
Prostate Urine microscopy and culture, urine cytology, PSA, CT, ultrasound
scan, full blood count, renal function, liver function test, X-ray
Opiates, paracetamol, non-steroidal
anti-inflammatory tablets, α-blockers,
5α-reductase enzyme inhibitors
Bladder Urine microscopy and culture, urine cytology, PSA, CT, ultrasound
scan, full blood count, renal function, liver function test, intravenous
pyelogram
Nil
Colorectal Colonoscopy/gastroscopy, CT/ultrasound scan, stool culture and
sensitivity, cytology, faecal occult blood test, full blood count, renal
function test, liver function test, erythrocyte sedimentation rate, iron
studies, lipase, calcium, magnesium, phosphate
Paracetamol, iron supplements, iron
injections, laxatives, antispasmodics,
vitamin C, opiates
Pancreatic Full blood count, renal function test, liver function test, blood
glucose, coagulation profile, amylase, lipase, bilirubin, CT,
ultrasound scan/bone scan
Paracetamol, codeine, opiates,
cholestyramine, vitamin B12,
proton-pump inhibitors
Oesophageal Barium swallow/chest X-ray, CT/ultrasound scan, gastroscopy, full
blood count, renal function test, liver function test, iron studies,
coagulation studies, urea breath test/Helicobacter pylori serology
Antiemetics, food supplements,
proton-pump inhibitors
Cervical Vaginal swab MCS/Pap smear, human papilloma virus cytology,
urine culture and sensitivity, chlamydia, gonorrhoea PCR, human
immune deficiency virology, hepatitis B, hepatitis C, syphilis
serology, VDRL, full blood count, renal function test, liver function
test, ferritin, ultrasound scan/CT, colposcopy/endoscopy
Nil
Endometrial US pelvic/vaginal, full blood count, renal function test, liver function
test, iron studies, coagulation studies, Pap smear/swab, urine
culture and sensitivity, X-ray, CT, hysteroscopy
Oestrogen replacement vaginal
pessaries
MCS, mid stream urine; PSA, prostate-specific antigen; US, ultrasound; VDRL, Venereal Disease Research Laboratory.
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for their selected patient management strategy. Despite
these limitations, the results from this study reveal an
important need to examine how patient outcomes are
affected by the ways GPs respond to patients’ cancer
symptoms.
Comparison with other literature
Although the ﬁndings from this study may cause
concern, the study is limited by the use of video-
vignettes, which prevented participants from interacting
with the patient or their families. Such interactions may
increase the prospect of referral.21 Research also sug-
gests that a cancer diagnosis can be missed where there
are: atypical presentations, non-speciﬁc presentations,
very low prevalence rates, comorbidities and/or percep-
tual features.22 All cases in this study were typical and
devoid of distracting features. Furthermore, participants
were more inclined to manage the patient with investiga-
tions or a referral when using the interactive referral pro
forma. As the pro forma required detailed patient infor-
mation, participants may have been prompted to request
additional evidence—like that of a pathology report—
before referring the patient to a specialist. The risk in
this case is of false negative investigation ﬁndings.
Furthermore, a recent report on delayed cancer diagno-
ses noted a ‘lack of reporting culture in primary care
compared with acute hospitals… [As such] any analysis
will show only a small proportion of incidents in primary
care, and from general practice in particular’. 23 This
may explain the limited literature on potential delays to
cancer diagnosis within primary care. The data pre-
sented here suggest a risk of delay. The review also con-
cluded that some of the factors that contribute to
practitioner delay included: symptom misattribution
and/or no examination or investigation of malignancy.
The data presented in this paper support these
conclusions.
Implications for clinicians and policymakers
Results from this study suggest that some patients may
receive a delayed cancer diagnosis, even when they
present with typical cancer symptoms to a GP who can
access relevant diagnostic tests. There was limited evi-
dence that appropriate tests would be ordered, and a
signiﬁcant proportion of cases were not immediately
referred for further investigation or specialist opinion.
Therefore, better cancer outcomes may not be solely
explained by GP access to investigations, but rather to
other factors that were beyond the scope of this study.
These may include expedient access to specialists via
the private healthcare sector or different systems of
care.
Future directions
Research is required to understand how GPs ﬁlter and
use clinical information to determine the management
of patients who present with cancer symptoms.
Research is also required to identify efﬁcient and
effective referral pathways for these patients as they tra-
verse the health system and progress along the care
continuum.
CONCLUSION
Patients may receive a delayed cancer diagnosis, even
when they present with typical cancer symptoms to a GP
who can access relevant diagnostic tests. Although this
may be partly improved through improved access to
diagnostic tests, there are likely to be additional ele-
ments that inﬂuence the ways in which potential cancer
symptoms are identiﬁed and managed within the
context of primary care.
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